| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000018285 |
| Receipt No. | R000021165 |
| Scientific Title | Influence of ingestion of eicosapentaenoic acid-rich fish oil on muscle damage and delayed onset muscle soreness following eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial |
| Date of disclosure of the study information | 2015/07/14 |
| Last modified on | 2020/01/11 (Ver. 10) |
| Basic information | ||
| Public title | Influence of ingestion of eicosapentaenoic acid-rich fish oil on muscle damage and delayed onset muscle soreness following eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial | |
| Acronym | Influence of eicosapentaenoic acid on muscle damage and delayed onset muscle soreness | |
| Scientific Title | Influence of ingestion of eicosapentaenoic acid-rich fish oil on muscle damage and delayed onset muscle soreness following eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial | |
| Scientific Title:Acronym | Influence of eicosapentaenoic acid on muscle damage and delayed onset muscle soreness | |
| Region |
|
|
| Condition | |||
| Condition | muscle damage and delayed onset muscle soreness | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The purpose of this study is investigating the influence of eicosapentaenoic acid (EPA) for muscle damage and delayed onset muscle soreness following eccentric contractions. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1. After ingestion of tested materials for 8 weeks, subjects perform eccentric contraction (ECC) with elbow flexors. During ECC,
1) electromyogram 2) isotonic contraction torque 2. After ingestion of tested materials for 8 weeks, subjects perform eccentric contraction (ECC) with elbow flexors. Before and after ECC, 1) ultrasonic imaging analysis for elbow flexors 2) reactivity of electrical micro-stimulation 3) maximal isometric contraction torque 4) range of motion 5)muscle soreness measured as a visual analog scale 6)muscle soreness measured by algesiometer |
| Key secondary outcomes | 1. After ingestion of tested materials for 8 weeks, subjects perform eccentric contraction (ECC) with elbow flexors. During ECC, analyzing ultrasonic imaging for elbow flexors.
2. After ingestion of tested materials for 8 weeks, subjects perform eccentric contraction (ECC) with elbow flexors. Before and after ECC, testing blood makers (creatine kinase, myoglobin, IL-6, TNF-alpha). |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Tested material: EPA-rich fish oil
Dosage: 2.4g/day Duration: 8 weeks |
|
| Interventions/Control_2 | Tested material: corn oil
Dosage: 2.4g/day Duration: 8 weeks |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | Healthy male subjects | |||
| Key exclusion criteria | Subjects with
/regular resistance training /no exercise /serious liver, kidney, heart, respiratory, endocrine or metabolic diseases/ scheduled for surgery during this study/ administration of regular medication / food allergies to fish/ participation of other clinical trial during this study/ restriction of exercise/ any reason in the opinion of the lead principal investigator not to take part in this study |
|||
| Target sample size | 24 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Okayama University | ||||||
| Division name | Graduate School of Education | ||||||
| Zip code | 700-8530 | ||||||
| Address | 3-1-1 Tsushima-naka, Kita-ku, Okayama City, Okayama , Japan | ||||||
| TEL | 086-251-7750 | ||||||
| eisukeochi@cc.okayama-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Okayama University | ||||||
| Division name | Graduate School of Education | ||||||
| Zip code | 700-8530 | ||||||
| Address | 3-1-1 Tsushima-naka, Kita-ku, Okayama City, Okayama , Japan | ||||||
| TEL | 086-251-7750 | ||||||
| Homepage URL | |||||||
| eisukeochi@cc.okayama-u.ac.jp | |||||||
| Sponsor | |
| Institute | Okayama University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nippon Suisan Kaisha Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Juntendo University |
| Address | 1-1 Hiragagakuendai, Inzai, Chiba |
| Tel | 0476-98-1001 |
| ytsuchi@juntendo.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | https://upload.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000021165 |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508798/ | ||||||
| Number of participants that the trial has enrolled | 21 | ||||||
| Results | Compared with the control group, M-wave latency was significantly shorter in the fish oil group immediately after exercise (p = 0.040), MVC torque was significantly higher at 1 day after exercise (p = 0.049), ROM was significantly greater at post and 2 days after exercise (post; p = 0.006, day 2; p = 0.014), and there was significantly less delayed onset muscle soreness at 1 and 2 days after exercise (day 1; p = 0.049, day 2; p = 0.023). |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Healthy men |
||||||
| Participant flow | The subjects were randomly assigned to the fish oil group (n = 10) or control group (n = 11). The fish oil group consumed eight 300-mg EPA-rich fish oil softgel capsules (containing, in total, 600 mg EPA and 260 mg DHA) per day for 8 weeks before the exercise, and continued this for a further 5 days. The control group consumed an equivalent number of placebo capsules. |
||||||
| Adverse events | Nothing |
||||||
| Outcome measures | M-wave latency, MVC torque, ROM, upper arm circumference, DOMS |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021165 |